<DOC>
	<DOCNO>NCT00081315</DOCNO>
	<brief_summary>The primary objective study ass activity subcutaneous ( SC ) amifostine incidence severity acute radiochemotherapy-induced esophagitis patient unresectable Stage IIIA IIIB non-small cell lung cancer ( NSCLC ) receiving combine modality therapy .</brief_summary>
	<brief_title>Subcutaneous Amifostine ( EthyolÂ® ) Prevention Radiochemotherapy-Induced Esophagitis Pneumonitis Patients With Unresectable Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>You may eligible study 18 year age older : Have UnResectable Stage IIIA IIIB Non Small Cell Lung Cancer Have never prior chemotherapy Paclitaxel Carboplatin Have never prior thoracic radiation therapy ( XRT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>- Non-Small cell lung cancer</keyword>
</DOC>